Phase 2 N=46 Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Risk for Colorectal Cancer
Primary: Number of Participants With Anti Muc-1 Antibody — 39 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=204 Adjuvant HIPEC in High Risk Colon Cancer
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
N/A N=99 Laparoscopic Complete Mesocolic Excision on Colon Cancer
Operation Finding · Complications · Pathology
Primary: Histopathological Outcomes Obtained Through the Surgeries — 20.3; 19.2 nodes
Phase 2 N=33 Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
Phase 2 N=64 Neoadjuvant Therapy for Locally Advanced Colon Cancer
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
Phase 2 N=24 Phase II Study of Irinotecan and Panitumumab
Esophageal Cancer
Primary: Response Rate (RR) — 6 percentage of participants
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 2 N=45 Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI
Adenomatous Polyp · Colorectal Cancer · Obesity
Primary: Change in Activated S6serine235 (i.e., the Ratio of pS6serine235/S6serine235) — 0.0228 weighted ratio of staining cells — p=> 0.773
Phase 2 N=124 Tecemotide (L-BLP25) in Rectal Cancer
Rectal Cancer
Primary: Change From Baseline in Tumor Immune Response Evaluated by Immunohistochemical (IHC) Analysis of Tumor Infiltrating Lymphocytes (TILs) at Week 14 (Post-surgery) — 0.609…
Phase 2 N=20 A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…
Phase 3 N=135 Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon
Crohn's Disease
Primary: Number of Subjects Without Mucosal Ulceration at Week 12 — 8; 17 Subjects — p=0.056
Phase 2 N=77 A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set — 54.5 percentage of participants
Phase 3 N=1,249 The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Colorectal Cancer
Primary: To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the…
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
Phase 1 N=20 Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Safety as Measured by the Number of Patients With Treatment Emergent Adverse Events (TEAEs), Grade 3 TEAEs, TEAEs Resulting in Death, TEAEs Related to Treatment and…
Phase 2 N=25 BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Pancreatic Cancer
Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants
Phase 2 N=4 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Colon Adenocarcinoma · High-Frequency Microsatellite Instability · Metastatic Malignant Solid Neoplasm
Primary: Percentage of Circulating DNA Clearance — 0 percentage of DNA cleared
Phase 2 N=16 Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Colon Cancer · Rectal Cancer
Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants
N/A N=386 Efficacy of Segmental Examination Twice of the Proximal Colon on Adenoma Detection
Colonic Polyps
Primary: Difference of Adenoma Detection Rate in the Proximal Colon Among 2 Group. — 0.236; 0.331 proportion of participants
N/A N=35 Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma
Colorectal Adenoma · Risk Reduction
Primary: Change in Beta Catenin Expression — 100; 100; 100; 100 percentage of positive cells
Phase 2 N=29 Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Malignant Neoplasms of Digestive Organs · Colorectal Cancer · Colon Cancer
Primary: Immune-related Best Overall Response Rate. — 1 Participants
Phase 2 N=11 TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Colorectal Cancer
Primary: Overall Response Rate — 0; 0; 5; 4 Participants
Phase 2 N=34 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
Colorectal Cancer · Cancer of Gastrointestinal Tract
Primary: Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA) — 0; 0; 0; 2 Participants
Phase 2 N=21 MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Colorectal Neoplasms
Primary: pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced…
Phase 2 N=32 Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Phase 2 N=13 Genistein in Treatment of Metastatic Colorectal Cancer
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
Phase 2 N=53 Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Ulcerative Colitis
Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN
Phase 2 N=30 Lymphatic Mapping for Sentinel Node Identification and Analysis
Colorectal Cancer
Primary: Subjects in Which the SLN(s) Are Identified — 27 Participants
Phase 2 N=53 Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Colon Cancer · Colorectal Cancer · Rectal Cancer
Primary: Part 1: Number of Participants With Dose-limiting Toxicities — 0 participants